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Abstract
Background: Epidemiological studies in atrial fibrillation (AF) illustrate that clinical complexity increase the risk of
major adverse outcomes. We aimed to describe European AF patients’ clinical phenotypes and analyse the
differential clinical course.
Methods: We performed a hierarchical cluster analysis based on Ward’s Method and Squared Euclidean Distance
using 22 clinical binary variables, identifying the optimal number of clusters. We investigated differences in clinical
management, use of healthcare resources and outcomes in a cohort of European AF patients from a Europe-wide
observational registry.
Results: A total of 9363 were available for this analysis. We identified three clusters: Cluster 1 (n = 3634; 38.8%)
characterized by older patients and prevalent non-cardiac comorbidities; Cluster 2 (n = 2774; 29.6%) characterized
by younger patients with low prevalence of comorbidities; Cluster 3 (n = 2955;31.6%) characterized by patients’
prevalent cardiovascular risk factors/comorbidities. Over a mean follow-up of 22.5 months, Cluster 3 had the highest
rate of cardiovascular events, all-cause death, and the composite outcome (combining the previous two) compared
to Cluster 1 and Cluster 2 (all P < .001). An adjusted Cox regression showed that compared to Cluster 2, Cluster 3
(hazard ratio (HR) 2.87, 95% confidence interval (CI) 2.27–3.62; HR 3.42, 95%CI 2.72–4.31; HR 2.79, 95%CI 2.32–3.35),
and Cluster 1 (HR 1.88, 95%CI 1.48–2.38; HR 2.50, 95%CI 1.98–3.15; HR 2.09, 95%CI 1.74–2.51) reported a higher risk
for the three outcomes respectively.
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Conclusions: In European AF patients, three main clusters were identified, differentiated by differential presence of
comorbidities. Both non-cardiac and cardiac comorbidities clusters were found to be associated with an increased
risk of major adverse outcomes.
Keywords: Atrial fibrillation, Clinical phenotypes, Cluster analysis, Clinical management, Major adverse outcomes
Background
Atrial fibrillation (AF) is a cardiovascular condition
which has a multifactorial origin, with several cardiovas-
cular (CV) and non-CV risk factors and comorbidities
significantly contributing to the development of incident
AF cases [1–3]. Indeed, epidemiological data clearly
demonstrates that the concomitant presence of multiple
risk factors/comorbidities increases the risk of develop-
ing AF [2, 4]. Moreover, patients with AF have a high
prevalence of various CV (i.e. heart failure, stroke, cor-
onary artery disease, peripheral artery disease) and non-
CV comorbidities, intended as non-cardiac or vascular
related (i.e. diabetes mellitus, chronic kidney disease,
gastric diseases, chronic obstructive pulmonary disease),
as well as a high rate of multi-morbidity [4–7].
Cluster analysis is a data-driven approach which helps
to improve clinical phenotype identification and classifi-
cation, which has been applied to the study of several
CV diseases [8–11]. Cluster analysis helps to identify the
relevant clinical phenotypes, but has been applied to AF
in relatively few studies [10–13]. In those studies which
investigated this particular approach, cluster analysis
helped to identify patients with similar clinical character-
istics which were different between the various groups
(more or less prevalence of risk factors and comorbidi-
ties combined together, i.e. ‘clinical phenotypes’), entail-
ing differential management approach and differential
risk for adverse outcomes, hence demonstrating how in
groups of patients with different clinical characteristics
AF can have a different clinical course [10–13].
Thus far, no large European AF cohort has been inves-
tigated to elucidate which are the most common clinical
phenotypes in patients presenting with AF. Indeed, as
demonstrated by previous literature, most of the cohorts
examined so far were from North America and Asia
[10–13]. Also a systematic review of machine-learning-
based studies, an even more sophisticated form of clus-
ter analysis, on disease definition and risk prediction
found that most of the studies were based on North
America cohorts [14].
The European Society of Cardiology (ESC) - European
Heart Rhythm Association (EHRA) EURObservational
Research Programme in AF (EORP-AF) General Long-
Term Registry is the largest contemporary observational
non-industry sponsored study on European AF patients
presenting to cardiology centers. The aim of this report
from the EORP-AF is to study the most relevant clinical
phenotypes in terms of multi-morbidity clusters among
European AF patients. Second, we aimed to analyse their
impact in terms of clinical management, healthcare re-
sources use, and major adverse outcomes.
Methods
The ESC-EHRA EORP Atrial Fibrillation General Long-
Term Registry is a multicenter observational registry
held by the ESC and endorsed by the EHRA. The Gen-
eral Long-Term Registry has been preceded by the Gen-
eral Pilot Registry [15–18]. The EORP-AF General
Long-Term Registry is a prospective, observational, mul-
ticenter registry established by the ESC in 27 participat-
ing countries. The study enrolled consecutive AF
patients presenting in 250 cardiology practices, both in-
and outpatient settings. The detailed description of the
study design, baseline characteristics and 1-year follow-
up results have been provided previously [19, 20].
Briefly, all AF patients enrolled had AF documented
within 12 months before enrollment, based on electro-
cardiographic proof. All patients were ≥ 18 years old and
provided written informed consent. Enrollment was
undertaken from October 2013 to September 2016, with
1-year follow-up performed until to September 2018.
Baseline and follow-up data were completed into a cen-
tralized electronic case report (eCRF) form by each in-
vestigator. According to its observational nature, only a
limited set of variables, related to baseline thrombo-
embolic and bleeding risk, baseline comorbidities and
pharmacological therapy, had to be compulsory filled.
‘Unknown’ value, when provided, was considered as
missing and then not considered. As reported in this
study, more than 80% of patients reported a valid data
for the core variables (Table 1 and Table 2). Patient data
were obtained after the signing of a written informed
consent by each patient, following the approval of study
protocol by an Institutional Review Board/Ethic Com-
mittee. The study was firstly approved by the National
Coordinators’ main institutions (listed in the Additional
file 1) and subsequently was authorized by each periph-
eral site under the responsibility of the lead contact and
study team (all listed in the Additional file 1), according
to the specific national and local regulation. Any details
regarding approval numbers for the study protocol re-
garding any specific site could be obtained from the
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Table 1 Baseline characteristics according to patient clusters










Age, years Median [IQR] 73 [65–78] 65 [56–72] 73 [66–78] < .001
Age classes, n (%) < .001
< 65 years 865 (23.8) 1351 (48.7) 659 (22.3)
65–74 years 1216 (33.5) 910 (32.8) 1039 (35.2)
75–84 years 1282 (35.3) 441 (15.9) 1068 (36.1)
≥ 85 years 271 (7.5) 72 (2.6) 189 (6.4)
Females, n (%) 1604 (44.1) 964 (34.8) 1138 (38.5) < .001
Overweight/obese, n (%) 755 (20.8) 1666 (60.1) 1619 (54.8) < .001
Smoking habit, n (%) 1218 (33.5) 996 (35.9) 947 (32.0) 0.008
Alcohol habit, n (%) 1088 (33.7) 1004 (41.0) 786 (29.8) < 0.001
Reason for admission, n (%) < .001
AF 2427 (66.8) 2299 (82.9) 1571 (53.2)
Other CV 1034 (28.5) 400 (14.4) 1221 (41.3)
Other non-CV 173 (4.8) 75 (2.7) 163 (5.5)
Site of admission, n (%) < .001
Hospital facility 1783 (49.1) 1261 (45.5) 1650 (55.8)
Outpatient facility 1851 (50.9) 1513 (54.5) 1305 (44.2)
Type of AF, n (%) 9360 < .001
First detected 547 (15.1) 532 (19.2) 373 (12.6)
Paroxysmal 936 (25.8) 865 (31.2) 692 (23.4)
Persistent 693 (19.1) 641 (23.1) 496 (16.8)
Long-standing persistent 143 (3.9) 114 (4.1) 134 (4.5)
Permanent 1256 (34.6) 577 (20.8) 1210 (41.0)
Unknown 58 (1.6) 44 (1.6) 49 (1.7)
CHA2DS2-VASc score, median [IQR] 9358 3 [2–4] 2 [1–3] 4 [3–5] < .001
CHA2DS2-VASc quartiles, n (%) < .001
Q1 (0–2) 1253 (34.5) 1834 (66.2) 520 (17.6)
Q2 (3) 887 (24.4) 483 (17.4) 598 (20.3)
Q3 (4) 777 (21.4) 312 (11.3) 734 (24.9)
Q4 (≥ 5) 716 (19.7) 143 (5.2) 1101 (37.3)
High TE risk, n (%) 9358 2865 (78.9) 1351 (48.7) 2771 (93.8) < .001
HAS-BLED score, median [IQR] 2 [1–2] 1 [0–2] 2 [1–3] < .001
High bleeding risk, n (%) 616 (17.0) 172 (6.2) 809 (27.4) < .001
EHRA score, median [IQR] 9362 2 [1–2] 2 [1–2] 2 [1–2] .002
EHRA II-IV, n (%) 9362 1892 (52.1) 1613 (58.2) 1536 (52.0) < .001
Previous stroke, n (%) 358 (9.9) 40 (1.4) 157 (5.3) < .001
Previous thromboembolic events, n (%) 529 (14.6) 193 (7.0) 325 (11.0) < .001
Hypertension, n (%) 2230 (61.4) 1253 (45.2) 2266 (76.7) < .001
Heart failure, n (%) 1327 (36.5) 419 (15.1) 1658 (56.1) < .001
Diabetes mellitus, n (%) 297 (8.2) 177 (6.4) 1613 (54.6) < .001
Lipid disorder, n (%) 1356 (38.4) 874 (32.5) 1512 (52.5) < .001
Congenital heart disease, n (%) 50 (1.4) 24 (0.9) 29 (1.0) .24
Valvular disease, n (%) 2200 (60.5) 615 (22.2) 1724 (58.3) < .001
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Corresponding Authors, upon reasonable request. The
study was performed according to the European Union
Note for Guidance on Good Clinical Practice CPMP/
ECH/135/95 and the Declaration of Helsinki.
Symptomatic status was defined according to EHRA
score [1]. Thromboembolic risk was defined according
to CHA2DS2-VASc score [1]. Bleeding risk was defined
according to HAS-BLED score [1]. Both CHA2DS2-
VASc and HAS-BLED scores were computed according
to the original schemes. High thromboembolic risk was
defined as CHA2DS2-VASc ≥ 2 in males and ≥ 3 in fe-
males. High bleeding risk was defined for HAS-BLED ≥
3. We have also examined distribution of CHA2DS2-
VASc quartiles across the clusters. Multi-morbidity was
defined as the concomitant presence of at least 2 differ-
ent comorbidities [21]. Frailty was defined based on a
40-item frailty index ≥ 0.25 built according to Rockwood
and Mitnitski [22]. Polypharmacy was defined as the
concomitant use of ≥ 5 drugs [23]. Additionally, we ex-
amined the distribution of comorbidities and concomi-
tant drug distribution. Adherence to the Atrial
fibrillation Better Care (ABC) pathway was defined ac-
cording to a previously published study [24]. Briefly, the
ABC pathway has been proposed to streamline inte-
grated care and holistic management in AF patients and
is based on the following: (i) avoid stroke with anticoa-
gulation; (ii) better symptom management with patient-
centred symptom-directed decisions on rate or rhythm
Table 1 Baseline characteristics according to patient clusters (Continued)










CAD, n (%) 1093 (30.1) 273 (9.8) 1311 (44.4) < .001
CIED implant, n (%) 364 (10.2) 166 (6.1) 400 (13.7) < 0.001
Chronic kidney disease, n (%) 138 (3.8) 58 (2.1) 911 (30.8) < .001
History of bleeding, n (%) 311 (8.6) 23 (0.8) 156 (5.3) < .001
COPD, n (%) 446 (12.3) 80 (2.9) 267 (9.0) < .001
Anaemia, n (%) 176 (4.8) 14 (0.5) 268 (9.1) < .001
Predisposition to bleeding, n (%) 76 (2.1) 18 (0.6) 81 (2.7) < .001
Peripheral arterial disease, n (%) 297 (8.2) 131 (4.7) 318 (10.8) < .001
Liver disease, n (%) 125 (3.4) 17 (0.6) 79 (2.7) < .001
OSAS, n (%) 83 (2.3) 230 (8.3) 127 (4.3) < .001
Neoplasm, n (%) 513 (14.1) 40 (1.4) 162 (5.5) < .001
Hyperthyroidism, n (%) 305 (8.4) 47 (1.7) 84 (2.8) < .001
Hypothyroidism, n (%) 509 (14.0) 49 (1.8) 334 (11.3) < .001
Multi-morbidity, n (%) 3151 (86.9) 1312 (47.3) 2877 (97.6) < .001
Comorbidities, N Median [IQR] 3 [2–4] 1 [0–2] 4 [3–6]
Comorbidities quartiles, n (%) < .001
Q1 (0–2) 1289 (35.5) 2134 (76.9) 337 (11.4)
Q2 (3) 901 (24.8) 313 (11.3) 518 (17.6)
Q3 (4–5) 1024 (28.2) 272 (9.8) 1174 (39.8)
Q4 (≥ 6) 414 (11.4) 55 (2.0) 918 (31.2)
Frailty, n (%) 571 (16.5) 185 (7.0) 1003 (35.5) < .001
Polypharmacy, n (%) 9301 1801 (49.9) 941 (34.1) 2162 (73.7) < .001
Drugs, N Median [IQR] 4 [3–6] 4 [2–5] 6 [4–7]
Drug quartiles, n (%) < .001
Q1 (0–3) 1053 (29.2) 1272 (46.2) 345 (11.8)
Q2 (4–5) 1457 (40.3) 1018 (36.9) 1034 (35.2)
Q3 (6) 564 (15.6) 264 (9.6) 589 (20.1)
Q4 (≥ 7) 537 (14.9) 202 (7.3) 966 (32.9)
Legend: AF atrial fibrillation, CAD coronary artery disease, CIED cardiac implantable electronic device, CKD chronic kidney disease, COPD chronic obstructive
pulmonary disease, CV cardiovascular, IQR interquartile range, OSAS obstructive sleep apnoea syndrome, PAD peripheral artery disease, RFs risk factors,
TE thromboembolic
Proietti et al. BMC Medicine          (2021) 19:256 Page 4 of 17
control; (iii) cardiovascular risk factor and comorbidity
optimization including lifestyle changes [25]. Adherence
to the ABC pathway has consistently been associated
with reduction in risk for major clinical outcomes asso-
ciated with AF [26]. According to the eCRF rate/
rhythm control strategy, as well the use of specific
medical techniques (electric or pharmacological car-
dioversion, catheter ablation), were evaluated both
priori admission/consultation and during admission/
consultation. All the baseline variables were estab-
lished regardless of the clustering process and accord-
ing to previous international definitions; hence, no a
priori difference can be determined according to the
various clusters.
Clustering process
We performed an agglomerative hierarchical cluster ana-
lysis based on Ward’s Minimum Variance Method to
minimize the total within-cluster variance and we se-
lected the squared Euclidean as measure of distance or
dissimilarity. The squared Euclidean distance was used
since only dichotomous variables were selected. The aim
of the analysis was to identify the optimal number of
clusters that were homogenous and indicative of a clinic-
ally relevant phenotypic subgroup of AF patients without
a priori knowledge of the outcomes. We a priori selected
22 clinical variables as follows: age, sex, heart failure,
coronary artery disease, valvular disease, hypertension,
diabetes mellitus, ischemic stroke, peripheral ischemic
Table 2 Atrial fibrillation clinical management according to patient clusters
Cluster 1 Cluster 2 Cluster 3 P
Antithrombotic treatment
Any antiplatelet, n (%) 9356 708 (19.5) 304 (11.0) 812 (27.5) < .001
Any OAC, n (%) 9359 3143 (86.5) 2306 (83.2) 2563 (86.7) < .001
Any VKA, n (%) 9358 1833 (50.5) 1163 (42.0) 1639 (55.5) < .001
Any NOAC, n (%) 9354 1314 (36.2) 1145 (41.3) 925 (31.3) < .001
Antithrombotic pattern, n (%) < .001
No antithrombotic 217 (6.0) 318 (11.5) 142 (4.8)
Only antiplatelet 273 (7.5) 147 (5.3) 250 (8.5)
Only VKA 1524 (42.0) 1059 (38.2) 1228 (41.6)
Only NOAC 1182 (32.6) 1089 (39.3) 773 (26.2)
Antiplatelet + OAC 435 (12.0) 157 (5.7) 562 (19.0)
Primary management (before admission) < .001
Primary management strategy, n (%) 7753 < .001
Rate control 1371 (45.3) 802 (36.5) 1317 (52.0)
Rhythm control 1203 (39.8) 1083 (49.3) 852 (33.7)
Observation 452 (14.9) 311 (14.2) 362 (14.3)
Primary ECV, n (%) 7350 693 (24.1) 604 (28.5) 476 (20.2) < .001
Primary PCV, n (%) 7281 730 (25.6) 629 (29.9) 621 (26.6) .003
Primary catheter ablation, n (%) 7531 171 (5.8) 181 (8.4) 108 (4.4) < .001
Management during admission/consultation <.001
Intervention planned/performed, n (%) 9363 1285 (34.6) 1150 (41.5) 984 (33.3) <.001
ECV, n (%) 3392 566 (45.0) 628 (54.6) 379 (38.5) < .001
PCV, n (%) 3392 304 (24.2) 204 (17.7) 245 (24.9) < .001
Catheter ablation, n (%) 3392 176 (14.0) 261 (22.7) 100 (10.2) < .001
Management strategy at discharge, n (%) < .001
Rate control 1724 (47.5) 984 (35.5) 1522 (51.7)
Rhythm control 1365 (37.6) 1333 (48.1) 981 (33.3)
Observation 537 (14.8) 452 (16.3) 442 (15.0)
ABC pathway adherence, n (%) 666 (30.8) 655 (34.5) 431 (26.2) < .001
Legend: ECV electrical cardioversion, NOAC non-vitamin K antagonist oral anticoagulant, OAC oral anticoagulant, PCV pharmacological cardioversion, VKA vitamin
K antagonist
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events, liver disease, chronic obstructive pulmonary dis-
ease, anaemia, dementia, any cardiomyopathy, hyperthy-
roidism, hypothyroidism, chronic kidney disease,
obstructive sleep apnoea syndrome, malignancy, body
mass index. All variables were considered as categor-
ical—either present or absent. Age and body mass index
were dichotomized, according to usual clinical practice,
as age < 75 and ≥ 75 years and body mass index < 25 kg/
m2 (normal BMI) and ≥ 25 kg/m2 (overweight/obese).
From the EORP-AF dataset, a total of 9363 (84.8%)
were found to have all data available for the 22 variables
and were included in the analysis. The clustering algo-
rithm begins with each element (i.e. patient) in a separ-
ate cluster and then proceeds with a ‘bottom-up’
approach grouping each cluster with the most similar
one until all clusters become one. The hierarchical clus-
tering process is visually represented by a dendrogram
graph in which vertical lines represent clusters that are
joined together and the position of an horizontal line on
the scale indicates the rescaled distance at which clusters
were joined (the higher is the rescaled distance at which
clusters combine on the y-axis, the more dissimilarity
exists between clusters since they joined nearer to the
final point of the dendrogram, in which the clusters be-
come one). Ward Linkage coefficients provided a mean
to determine the heterogeneity between clusters by pro-
viding the difference in Euclidean distances over which
clusters are joined (i.e. the difference between subse-
quent horizontal lines on the dendrogram) with larger
distances indicating greater heterogeneity between the
clusters joined at that step. By examining the dendro-
gram produced by the clustering process and consider-
ing the Ward Linkage coefficients, we found that the
distance between the points in which the elements
grouped together (between 10 and 15 on the y-axis) be-
came larger and consequently the groupings became
more heterogeneous after being expanded to 3 clusters.
Therefore, the 3-cluster model was used in this study.
Outcomes
To evaluate the comprehensive impact of different AF
clinical phenotypes, we considered a large set of out-
comes. First, we examined the differential use of health-
care resources according to the three clusters. In
patients enrolled during hospitalization, we evaluated
the overall length of stay. Further, we recorded and ana-
lysed the occurrence of cardiology and internal medi-
cine/general practitioner visits, as well as emergency
room admissions (all intended as a binary variable as ‘at
least one visit/admission’), in the three clusters identi-
fied, occurred separately during the first and second year
of follow-up. Second, we considered several major clin-
ical adverse events, throughout the follow-up period.
The primary clinical outcomes were as follows: (i)
cardiovascular events including the occurrence of any
thromboembolic event (including stroke, transient ische-
mic attack and any peripheral embolism), any acute cor-
onary syndrome and CV death; (ii) all-cause death; and
(iii) a final composite outcome of CV events and/or all-
cause death. All primary outcomes were analysed with a
time-to-event and intention-to-treat approach, with ob-
servation censored after the first event occurred. Add-
itionally, we evaluated the occurrence of several
secondary clinical outcomes: (i) any bleeding; and hos-
pital readmission for (ii) any cause; (iii) CV-related; (iv)
AF; (v) cardiovascular but non-AF related; and (vi) any
non-CV cause. These secondary outcomes, given the
lack of dates, were not analysed with a time-to-event ap-
proach. All outcomes were assessed by clinical visit or
telephonic interview with patient or next of kind and re-
ported by investigators. Each event was not centrally ad-
judicated but categorized according to investigator’s
clinical evaluation. All data regarding outcomes were
collected before the analysis was planned and performed;
hence, no difference in assessment of outcomes exists
according to the clusters.
Statistical analysis
Continuous variables were expressed as mean and stand-
ard deviation or median and IQR, and differences across
the clusters were evaluated according to one-way ana-
lysis of variance (ANOVA) and Kruskal-Wallis one-way
ANOVA, respectively. Categorical variables were
expressed as counts and percentages and differences
across clusters were evaluated according to the chi-
squared test. A logistic regression model, adjusted for
type of AF and EHRA score, was compiled to examine
the association between clusters and use of oral anti-
coagulant (OAC) therapy.
To evaluate the differences in length of hospital stay
between the three clusters, a one-way analysis of co-
variance (ANCOVA) model, adjusted for type of AF and
EHRA score, was used. To analyze the association be-
tween clusters and other healthcare use resources, a lo-
gistic regression model was used, adjusted for type of
AF, EHRA score and use of OAC.
Differences in cumulative risk for the three main study
outcomes were evaluated using log-rank test and drafted
according to Kaplan-Meier curves. To investigate the as-
sociation between the three clusters and the study pri-
mary clinical outcomes, a Cox regression analysis,
adjusted for type of AF, EHRA score and use of OAC.
The association between the three clusters and the sec-
ondary clinical outcomes utilized a logistic regression
model, adjusted for type of AF, EHRA score and use of
OAC.
Finally, to understand whether the application of a
more comprehensive and integrated clinical
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management could have had an impact on the occur-
rence of clinical outcomes, we performed an analysis to
assess the impact of adherence to the ABC pathway on
the composite outcome of CV events and all-cause
death, according to the three clusters. A Cox regression
model for ABC vs. non-ABC and each ABC criterion,
adjusted for type of AF, EHRA score and use of OAC,
was performed. All logistic regression analysis results
were reported as odds ratio (OR) and 95% confidence
interval (CI). All Cox regression analysis results were re-
ported as hazard ratio (HR) and 95% CI. No formal
interaction analysis was performed, and missing data
were just considered as missing with no imputation ana-
lysis performed. A two-sided p < 0.05 was considered
statistically significant. All analyses were performed
using SPSS statistical software version 25.0.0.1 (IBM,
NY, USA) for MacOS.
Results
Among the overall 11,096 patients originally enrolled in
the study, a total of 9363 (84.8%) were included in this
analysis. The 1733 remaining patients were excluded
based on missing data regarding the variables used for
the clustering process, Median [IQR] age was 71 [62-77],
with 3706 (39.6%) females and a median [IQR]
CHA2DS2-VASc equal to 3 [2–4] (Table 1). According
to the methods described above, we identified 3 clusters,
characterized as follows.
Cluster 1—older patients with non-cardiac comorbidities
A total of 3634 (38.8%) patients were in Cluster 1. Me-
dian [IQR] age was 73 [65-78] years, with 1553 (42.7%)
patients being ≥ 75 years and the largest proportion of
females compared to the other clusters (P < .001). Con-
versely, the proportion of overweight/obese patients was
the lowest in Cluster 1 compared to Clusters 2 and 3 (P
< .001). Patients in Cluster 1 had a clinical history more
burdened with previous stroke, thromboembolic and
bleeding events (P < .001) and a higher prevalence of
several non-cardiovascular comorbidities, compared to
other clusters (Table 1). Mean CHA2DS2-VASc and
HAS-BLED scores were higher than in patients in Clus-
ter 2, but lower than in patients in Cluster 3 (both P <
.001). In terms of CHA2DS2-VASc score quartiles, the
proportion of patients in Quartile 1 (Q1) (i.e. CHA2DS2-
VASc 0-2) was highest in Cluster 2, while was lowest in
Cluster 3 (Table 1).
Cluster 2—younger patients with few comorbidities
A total of 2774 (29.6%) patients were grouped in Cluster
2. This cluster included younger patients (median [IQR]
age 65 [56-72] years) compared to the other two clusters
(P < .001). This cluster had the largest proportion of
overweight/obese patients, who were also more likely to
be admitted for AF as primary diagnosis and enrolled at
an outpatient facility. Moreover, patients in this cluster
were those more likely smoking and drinking alcohol. In
addition, patients in Cluster 2 were more likely to have
first detected and paroxysmal AF and were more symp-
tomatic, but less likely to have permanent AF (P < .001)
than those in the other clusters. Patients in Cluster 2
generally had less comorbidities than patients in other
clusters (P < .001). Thromboembolic and bleeding risks
were the lowest, together with prevalence of multi-
morbidity, polypharmacy and frailty among patients in
Cluster 2.
Cluster 3—older patients with high prevalence of
cardiovascular risk factors and comorbidities
A total of 2955 (31.6%) patients were included in Cluster
3. Median [IQR] age was 73 [66-78] years, with 1257
(42.5%) females. Patients in Cluster 3 were more likely
to be admitted for cardiovascular reasons other than AF
(P < .001) and more commonly had permanent AF com-
pared to other clusters (P < .001). Cluster 3 patients
were more likely to be enrolled at hospital admission (P
< .001). Patients in Cluster 3 had more prevalent CV risk
factors and clinical history of cardiac and vascular dis-
ease, with 2771 (93.8%) patients with high thrombo-
embolic risk and 809 (27.4%) with high bleeding risk. In
terms of CHA2DS2-VASc quartiles, patients in Q4 (i.e.
CHA2DS2-VASc ≥ 5) were more prevalent in Cluster 3,
and least so in Cluster 2 (Table 1). Accordingly, these
patients reported the highest prevalence of previous car-
diac implantable electronic device. Additionally, the
prevalence of multi-morbidity, frailty and polypharmacy
was highest in Cluster 3 compared to the other clusters
(all P < .001). When examining the median number of
comorbidities and concomitant drugs, both were highest
in Cluster 3 and progressively lower in Cluster 1
followed by Cluster 2. When looking at quartiles of co-
morbidities and concomitant drugs, patients in Q4 (re-
spectively comorbidities ≥ 6 and concomitant drugs ≥ 7)
were more commonly found in Cluster 3, and lower in
Clusters 1 and 2 (Table 1).
Based on baseline characteristics, we can ‘label’ the
three clusters (Fig. 1) as follows: (i) Cluster 1: older pa-
tients with prevalent non-cardiac comorbidities; (ii)
Cluster 2: younger patients with an overall low thrombo-
embolic risk and low comorbidity burden; and (iii) Clus-
ter 3: patients with prevalent cardiovascular risk factors
and comorbidities, at highest risk of adverse events.
Management of AF
Analysis of the management of AF according to the
three clusters is reported in Table 2. Use of antiplatelet
drugs was highest in Cluster 3 (P < .001), while use of
OAC was lowest in Cluster 2 (P < .001). Among OAC,
Proietti et al. BMC Medicine          (2021) 19:256 Page 7 of 17
vitamin K antagonists were more likely used in Cluster
3, with non-vitamin K antagonist OACs use more preva-
lent in Cluster 2 (both P < .001). Dual antithrombotic
therapy was more used in Cluster 3 (P < .001). When con-
sidering only those patients eligible for OAC treatment
(male patients with CHA2DS2-VASc ≥ 1 or female pa-
tients with CHA2DS2-VASc ≥ 2), we found substantially
similar prevalence of treatments, with the only exception
of prevalence of OAC which was higher in Cluster 2 than
in the others (P = .004) (Additional file 1, Table S1).
After adjustment for type of AF and EHRA score,
compared to those in Cluster 2, both patients in Cluster
1 and in Cluster 3 were more likely prescribed with
OAC (OR 1.20, 95% CI 1.05–1.39 and OR 1.17, 95% CI
1.01–1.36, respectively). Among OAC users, Cluster 1
and Cluster 3 were significantly associated with greater
vitamin K antagonist use compared to non-vitamin K
antagonist OACs, when compared to Cluster 2 (adjusted
OR 1.21, 95% CI 1.08–1.36 and OR 1.45, 95% CI 1.29–
1.63, respectively).
Prior admission/consultation, a rate control strategy
occurred more often among patients in Cluster 3, while
a rhythm control strategy was more often used in Clus-
ter 2 (P < .001). All rhythm control strategies, except for
pharmacological cardioversion, were more prevalent in
Cluster 2 than in the other clusters (P < .001, P = .003
and P < .001, respectively).
During the index admission/consultation, a rhythm
control intervention was planned/performed more fre-
quently in Cluster 2 (P < .001). Electrical cardioversion
and catheter ablation were more likely used in Cluster 2,
while pharmacological cardioversion was more common
in Clusters 1 and 3 (all P < .001). At discharge, a rate
control strategy was more likely used in Cluster 3 and
patients in Cluster 3 were less likely managed as adher-
ent to ABC pathway (P < .001).
Use of healthcare resources
Among the 4694 patients enrolled during a hospital ad-
mission, mean [standard deviation] length of stay was
progressively lower in patients in Cluster 3 (8.07 [8.50]
days), Cluster 1 (6.52 [7.29] days) and Cluster 2 (4.36
[6.33] days) (P < .001 for the overall model and for dif-
ferences between each cluster). After adjustment for
EHRA score and type of AF, differences in overall length
of stay remained significant (F = 72.215, P < .001).
During follow-up, use of healthcare resources
(Table 3) differed significantly among the three clus-
ters. Patients in Cluster 1 and Cluster 3 were more
likely to have at least one internal medicine/general
practitioner visit both at 1 year and 2 years, even
after adjustments (see Table 3). Patients in Cluster 3
were more likely to have at least one emergency
Fig. 1 Patients’ cluster membership. Legend: CV = cardiovascular; RFs = risk factors
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room visit within the first 12 months of follow-up
(OR 1.50, 95% CI 1.29–1.75).
Major adverse events
Outcomes were assessed over a median [IQR] 731
[701-749] days of follow-up (Table 4). A progressively
higher rate of events was found from Cluster 2 to
Cluster 1 and Cluster 3 for the occurrence of cardio-
vascular events, all-cause death, composite outcomes
and any cardiovascular non-AF-related hospital re-
admission (all P < .001) (Table 4). Occurrence of any
bleeding and any non-CV-related hospital readmission
was significantly lower in Cluster 2, while a higher
rate of AF-related readmission was found. A non-
significant trend for a higher rate of any readmission
and any cardiovascular readmission was evident for
Cluster 3 (Table 4). Adjusted logistic regression ana-
lyses (Fig. 2) found a higher risk for all the secondary
outcomes in Cluster 1 and Cluster 3, except the risk
for any AF-related readmission, which was lower for
both these clusters.
Regarding the main clinical study outcomes, Kaplan-
Meier curves (Fig. 3) show a progressively higher cumu-
lative risk across the three clusters for all the main study
outcomes. Adjusted Cox regression analyses (Table 5)
found that compared to Cluster 1, Cluster 2 and Cluster
3 were associated with a progressively higher risk for all
the three study primary outcomes.
Adherence to ABC pathway and outcomes according to
clusters (Table 6)
In Cluster 1, we found that while the adherence to the
overall ABC pathway was not significantly associated
with a lower risk of the composite outcome, the ‘B’ cri-
terion showed a non-significant trend in inverse associ-
ation with the risk of event occurrence. In Cluster 2,
which was at a generally low thromboembolic risk, ad-
herence to ABC pathway was found to be associated to a
lower risk for the composite outcome, with no single
Table 3 Health resource use during follow-up according to patient clusters
Cluster 1 Cluster 2 Cluster 3 P
Cardiology visits 1Y, n (%) 2227 (75.1) 1802 (74.5) 1693 (73.3) .34
OR [95% CI]* 1.06 [0.93–1.20] Ref. 0.97 [0.85–1.20] –
Internal medicine/GP visits 1Y, n (%) 1208 (51.3) 909 (46.5) 1006 (52.4) < .001
OR [95% CI]* 1.24 [1.10–1.40] Ref. 1.30 [1.14–1.48] –
ER admissions 1Y, n (%) 494 (17.1) 390 (16.7) 490 (21.9) < .001
OR [95% CI]* 1.08 [0.93–1.26] Ref. 1.50 [1.29–1.75] –
Cardiology visits 2Y, n (%) 1788 (68.9) 1442 (68.2) 1355 (68.6) .88
OR [95% CI]* 1.03 [0.91–1.17] Ref. 1.00 [0.88–1.15] –
Internal medicine/GP visits 2Y, n (%) 1124 (51.0) 808 (45.5) 876 (51.2) .001
OR [95% CI]* 1.27 [1.18–1.44] Ref. 1.29 [1.13–1.48] –
ER admissions 2Y, n (%) 352 (14.1) 287 (14.0) 297 (15.7) .25
OR [95% CI]* 1.02 [0.86–1.21] Ref. 1.16 [0.97–1.39] –
Legend: *adjusted for type of AF, EHRA score, use of OAC; 1Y 1 year follow-up, 2Y 2 years follow-up, CI confidence interval, ER emergency room, GP general
practitioner, OR odds ratio. For other acronyms, please see previous tables’ legends
Table 4 Major adverse clinical events according to patient clusters
N = 8701 Cluster 1 Cluster 2 Cluster 3 P
Cardiovascular events, n (%) 295 (8.7) 121 (4.7) 385 (14.1) < .001
All-cause death, n (%) 331 (9.8) 101 (3.9) 370 (13.6) < .001
Composite outcome, n (%) 502 (14.9) 187 (7.2) 571 (20.9) < .001
Any bleeding, n (%) 156 (4.6) 71 (2.7) 121 (4.5) < .001
Any readmission, n (%) 1264 (37.7) 940 (36.3) 1063 (39.3) .09
Any CV readmission, n (%) 816 (24.4) 592 (22.9) 694 (25.6) .06
Any AF readmission, n (%) 413 (12.3) 396 (15.3) 304 (11.2) < .001
Any CV non-AF readmission, n (%) 546 (16.3) 306 (11.8) 516 (19.1) < .001
Any non-CV readmission, n (%) 406 (12.1) 260 (10.0) 322 (11.9) .03
Legend: for acronyms, please see previous tables’ legends
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criterion being independently associated with lower risk.
Cluster 3 showed that full adherence to the ABC path-
way was strongly associated with a significant reduction
in the risk of adverse outcomes, but that the risk reduc-
tion was mainly associated with adherence to the ‘C’ cri-
terion (Table 6).
Discussion
In this cluster analysis derived from the ESC-EHRA
EORP-AF General Long-Term Registry, we showed that
three main clinical phenotypes can be identified among
European AF patients. The first cluster was character-
ized by older patients with a prevalent high burden of
non-cardiac comorbidities (Cluster 1); the second cluster
was associated with a younger age, with a low burden of
comorbidities and an overall low thromboembolic risk
(Cluster 2); in the third cluster, we observed older AF
patients with a high burden of CV risk factors and co-
morbidities, with an overall high burden of multi-
morbidity and frailty, and the highest thromboembolic
risk (Cluster 3). The three clusters showed clear differ-
ences in terms of OAC therapy and clinical manage-
ment, with a differential risk in long-term major adverse
events. Both Cluster 1 and Cluster 3 showed an overall
higher use of healthcare resources during follow-up and
a higher risk of major adverse events, particularly those
patients in Cluster 3.
Recently, machine-learning-based data analysis has
been increasing applied to biomedical scientific research,
even in cardiovascular health [27]. Among the more
basic machine-learning analyses, the unsupervised clus-
ter analysis has garnered attention, with studies in the
hypertension and heart failure cohorts [8, 28]. Use of
this analytic technique allows us to perform insightful
epidemiological analysis, allowing better risk stratifica-
tion, which could lead to more focused management
and treatment [8]. Thus far, cluster analysis in AF pa-
tients has been applied to AF patients only in two large
Fig. 2 Multivariable logistic regression analysis for secondary clinical outcomes. Legend: adjusted for type of AF, EHRA score, use of OAC; AF =
atrial fibrillation; CV = cardiovascular; OAC = oral anticoagulant
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Fig. 3 Kaplan-Meier curves for primary clinical study outcomes. Legend: A Cardiovascular events = log-rank 85.975, P < .001. B All-cause death =
log-rank 132.790, P < .001. C Composite outcome = log-rank 132.997, P < .001. All pairwise comparisons were significant for P < .001. Green line =
Cluster 2; orange line = Cluster 1; yellow line = Cluster 3
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observational studies, the ‘Outcomes Registry for Better
Informed Treatment of Atrial Fibrillation’ and the ‘Keio
Interhospital Cardiovascular Studies for AF’ registry; US
and Japanese cohorts, respectively [10, 11]. More re-
cently other two cluster analyses regarding large AF
datasets were published [12, 13]. In this context, our
study provides novel evidence, representing the first
large cluster analysis focused on European AF patients.
The current analyses demonstrate how the level and
the type of comorbidities are key essential elements in
differentiating AF patients with distinctive clinical needs
and long-term risks. Previous studies investigating clus-
ter analysis in AF patients have shown how specific clus-
ters characterized by a higher burden of comorbidities
and risk factors are associated with higher risk of major
adverse events during long-term follow-up [10–13]. The
results we provide not only underline the importance of
the role of comorbidities in determining the occurrence
of major adverse events, but also highlight the differen-
tial impact of non-CV and CV comorbidities. While on
one side some previous analyses regarding the use of
machine-learning systems, of which cluster analysis rep-
resents a primordial representative, underlined how sev-
eral methodological issues can limit the reliability and
reproducibility of such data, it is our opinion that put-
ting our data in the context of previous literature helps
to stress some important concepts about how not only
comorbidities are crucial in determining the risk of out-
comes, but is also important how they associate each
other and influence the natural history of the disease as
a whole.
The Framingham Heart Study previously showed
that AF patients with comorbidities have a consist-
ently increased risk for cardiovascular events and all-
cause death compared to those without [29]. In an
analysis from the ‘Apixaban for Reduction in Stroke
and Other Thromboembolic Events in Atrial Fibrilla-
tion’ trial, multi-morbidity was found to be associated
with an increased risk of adverse outcomes [7]. Fur-
thermore, in a registry-based analysis of hospitalized
AF patients, an increasing Charlson Comorbidity
Index, a validated tool to evaluate the level of multi-
morbidity, was directly associated with the occurrence
of stroke, major bleeding and all-cause death [6]. Our
cluster analysis demonstrates that not all the comor-
bidities carry the same risk. Indeed, while Cluster 1
demonstrates an increased risk, Cluster 3 showed a
significantly greater risk compared to Cluster 1.
The 2020 ESC guidelines on the management of AF
[1] introduce a paradigm shift promoting a more inte-
grated and holistic approach to AF diagnosis,
characterization and management, summarized as ‘CC
to ABC’. If the first ‘C’ relates to confirmation of AF
diagnosis, the second ‘C’ focused specifically on the need
to properly evaluate and characterize each AF patient, in
order to appropriately stratify their individual risk and
plan the best diagnostic and therapeutic pathway. Re-
garding the ‘characterization’ of AF patients, the ESC
guidelines recommends the ‘4S-AF scheme’ to provide a
‘structured characterization of AF and to streamline the
assessment of AF patients at different healthcare levels,
inform treatment decision-making and facilitate optimal
management of AF patients’ [30]. The 4S-AF scheme
suggests evaluating patients as follows: (i) stroke risk; (ii)
Table 5 Cox regression analysis for main study outcomes
Univariate Multivariablea
HR (95% CI) P HR (95% CI) P
Cardiovascular Events, n (%)
Cluster 1 1.85 [1.46–2.34] < .001 1.88 [1.48–2.38] < .001
Cluster 2 (Ref.) – – – –
Cluster 3 2.82 [2.24–3.55] < .001 2.87 [2.27–3.62] < .001
All-cause death, n (%)
Cluster 1 2.55 [2.03–3.21] < .001 2.50 [1.98–3.15] < .001
Cluster 2 (Ref.) – – – –
Cluster 3 3.55 [2.83–4.46] < .001 3.42 [2.72–4.31] < .001
Composite outcome, n (%)
Cluster 1 2.09 [1.74–2.51] < .001 2.09 [1.74–2.51] < .001
Cluster 2 (Ref.) – – – –
Cluster 3 2.81 [2.34–3.37] < .001 2.79 [2.32–3.35] < .001
Legend: aadjusted for type of AF, EHRA score, use of OAC. HR hazard ratio. For
other acronyms, please see previous tables’ legends
Table 6 Adherence to ABC pathway and outcomes according
to clusters
Composite outcome
HRa 95% CI P
Cluster 1
ABC vs. Non-ABC 0.89 0.66–1.21 .45
A Criterion 1.25 0.80–1.96 .34
B Criterion 0.59 0.34–1.01 .06
C Criterion 0.82 0.63–1.05 .12
Cluster 2
ABC vs. Non-ABC 0.62 0.40–0.97 .04
A Criterion 1.23 0.78–1.95 .38
B Criterion 0.63 0.28–1.41 .26
C Criterion 0.55 0.37–0.81 .002
Cluster 3
ABC vs. Non-ABC 0.53 0.36–0.76 < .001
A Criterion 1.14 0.38–3.38 .82
B Criterion 0.96 0.57–1.62 .87
C Criterion 0.71 0.54–0.93 .01
Legend: aadjusted for type of AF, EHRA score, use of OAC. For acronyms,
please see previous tables’ legends
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symptom severity; (iii) severity of AF burden; (iv) sub-
strate severity. Fully supporting the 4S-AF approach, our
analysis demonstrates how comprehensive clinical
characterization provides important information, delin-
eating a clear profile for each cluster, which also differ-
entiated patients in terms of healthcare needs and long-
term risks. Hence, the information gathered through the
clustering process can help in defining the patients’ risks
and determine strategies to improve their care and
management.
The differential impact of the ABC pathway under-
lines how the same treatment strategies can have dis-
tinct effects according to the clinical profile of the
patient. Also, the evidence that the ABC pathway is
more effective in the cluster with the greatest multi-
morbidity (Cluster 3), and that the effectiveness is
driven largely by the management of comorbidities,
emphasizes the prominent role of CV risk factors/co-
morbidities in determining adverse outcomes in AF
patients, while clearly demonstrating how a compre-
hensive management plan is clearly needed to im-
prove patient care, as well as a proper evaluation and
characterization.
Our data are also in line with more recent research
in the area of multi-morbidity, which now distin-
guishes patterns/clusters of conditions, clearly defined
in terms of sociodemographic, clinical and functional
characteristics, beyond the mere presence of multiple
conditions [31]. This analysis represents the first ap-
plication of this approach to a large European AF
population.
Results from the cluster analysis in AF patients
underline the importance of stratifying patients’ char-
acteristics and identify those clinical phenotypes more
prone to adverse events, beyond the mere focus on
thromboembolic risk, and to properly address pa-
tients’ care need and healthcare management plan. If
the clustering process is not easily applicable in clin-
ical daily life, information gathered from this analysis
reinforces the concept that the presence of comorbid-
ities increases the risk. Thus, we further reinforce the
need for implementation of the 4S-AF scheme to
characterize AF, which allows an easy and straightfor-
ward way for everyday clinical use, also helping to the
use and evaluation of quality indicators [32]. We be-
lieve it is important to underline that our data are
generated from a large Europe-wide cohort. Even
though patients were gathered principally from third-
level cardiology practices, they were collected
consecutively over the enrolment time and with a
minimal set of inclusion/exclusion criteria, reassuring
on the representativity of our data. Even though we
based our clustering analysis on a lower number of
variables, we think that the superimposable results, in
particular about the main characteristics of the clus-
ters and their impact on risk of outcomes, could re-
assure about the reliability of our analysis, with a
relevant generalisability of the results provided.
Limitations
The main limitation of the study relates to its obser-
vational nature, with a limited power to detect differ-
ences in subgroups which were not pre-specified in
the study design. Moreover, as an observational regis-
try, completeness of data is not as high as clinical
trial; hence, this aspect may have partially limited our
analytical capability. Notwithstanding, several paper
already published about the EORP-AF General Long-
Term Registry showed similar findings to other con-
temporary registries held in other geographical loca-
tions, both in terms of baseline characteristics and
follow-up data [19, 20]. Second, the data presented do
not imply causality, rather they describe a statistical
association. Furthermore, identified clusters may vary
according to patients’ characteristics and available
data and may change over time, since risk is dynamic
(changing with ageing and incident risk factors [33–
35]) and not a ‘one-off’ assessment. Moreover, no for-
mal interaction analysis was performed, and missing
data were just considered as missing with no imput-
ation analysis performed. Finally, the optimal number
of clusters can be difficult to determine since differ-
ent statistical algorithms may generate different re-
sults and the final selection of clusters was based in
part on investigator discretion, also no analysis re-
garding the between-cluster heterogeneity could have
been performed. The extent of the limitations sug-
gests caution in interpreting our findings. Notwith-
standing, we believe that given the large cohort
presented generated from the entire European terri-
tory confers a significant generalizability, even though
is necessary to take in mind the possible limitations
of such analyses [14].
Conclusions
In European AF patients, three main clinical clusters
were identified, older patients with non-cardiac co-
morbidities, a younger, low risk group and older pa-
tients with cardiac comorbidities. Both non-cardiac
and cardiac comorbidities clusters were found to be
associated with an increased risk of major adverse
outcomes.
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